Analytical Research Laboratories BioPharma

Oklahoma City, OK, United States

Analytical Research Laboratories BioPharma

Oklahoma City, OK, United States

Time filter

Source Type

Hanas J.S.,The University of Oklahoma Health Sciences Center | Hanas J.S.,Veterans Administration Medical Center | Peyton M.D.,The University of Oklahoma Health Sciences Center | Peyton M.D.,Veterans Administration Medical Center | And 13 more authors.
Cancer Investigation | Year: 2014

Serum mass profiling can discern physiological changes associated with specific disease states and their progression. Sera (86 total) from control individuals and patients with stage I nonsmall cell lung cancer or benign small pulmonary nodules were discriminated retrospectively by serum changes discerned by mass profiling. Control individuals were distinguished from patients with Stage I lung cancer or benign nodules with test sensitivities of 89% and 83%. Lung cancer patients versus those with benign nodules were distinguished with 80% sensitivity. This study exhibits progress toward a minimally-invasive aid in early detection of lung cancer and monitoring small pulmonary nodules for malignancy. Copyright © 2014 Informa Healthcare USA, Inc.


Hocker J.R.,The University of Oklahoma Health Sciences Center | Peyton M.D.,The University of Oklahoma Health Sciences Center | Lerner M.R.,The University of Oklahoma Health Sciences Center | Lerner M.R.,Veterans Affairs Medical Center | And 13 more authors.
Lung Cancer | Year: 2011

The goal of this study was to evaluate the usefulness of electrospray ionization-mass spectrometry (ESI-MS) technology to distinguish sera of early-stage lung cancer patients from control individuals. ESI-MS m/. z (mass divided by charge) data were generated from sera of 43 non-small cell lung cancer patients (pathological stages I and II) and 21 control individuals. Identifications of m/. z peak area significances between cancer and control ESI-MS sera spectra were performed using t-tests. A "leave one out" cross validation procedure, which mimics blinded sera analysis and corrects for "over-fitting" of data, yielded discriminatory cancer versus control distribution p value and ROC curve area value of <0.001 and 0.87, respectively. Analysis without the "leave one out" cross validation procedure yielded a ROC curve area of 0.99 for discrimination of sera from lung cancer patients versus control individuals. Predictive value measurements revealed overall test efficiency and sensitivity for distinguishing sera from lung cancer patients from controls (using "leave one out" cross validation) of 80% and 84%, respectively. ESI-MS serum analysis between control individuals and lung cancer patients who smoked or did not smoke had p values in ranges indicating that smoking effects are not pronounced in our analysis. These studies indicate that ESI-MS analyses of sera from early stage non-small cell lung cancer patients were helpful in distinguishing these patients from control individuals. © 2011 Elsevier Ireland Ltd.

Loading Analytical Research Laboratories BioPharma collaborators
Loading Analytical Research Laboratories BioPharma collaborators